Cardiomyopathy caused by lamin A/C gene mutations (LMNA cardiomyopathy) is characterized by increased myocardial fibrosis, which impairs left ventricular relaxation and predisposes to heart failure, and cardiac conduction abnormalities. While we previously discovered abnormally elevated extracellular signal-regulated kinase 1/2 (ERK1/2) activities in heart in LMNA cardiomyopathy, its role on the development of myocardial fibrosis remains unclear. We now showed that transforming growth factor (TGF)-b/Smad signaling participates in the activation of ERK1/2 signaling in LMNA cardiomyopathy. ERK1/2 acts on connective tissue growth factor (CTGF/CCN2) expression to mediate the myocardial fibrosis and left ventricular dysfunction. Studies in vivo demonstrate that inhibiting CTGF/CCN2 using a specific antibody decreases myocardial fibrosis and improves the left ventricular dysfunction. Together, these findings show that cardiac ERK1/2 activity is modulated in part by TGF-b/Smad signaling, leading to altered activation of CTGF/CCN2 to mediate fibrosis and alter cardiac function. This identifies a novel mechanism in the development of LMNA cardiomyopathy.
Introduction
One cause of dilated cardiomyopathy is dominant mutations in LMNA, the gene encoding A-type nuclear lamins, intermediate filament proteins of the nuclear envelope (1, 2) . Cardiomyopathy caused by LMNA mutations (i.e. LMNA cardiomyopathy) is characterized by increased myocardial fibrosis that impairs left ventricular relaxation and predisposes to heart failure, and cardiac conduction abnormalities (3) (4) (5) (6) . The onset of symptoms in LMNA cardiomyopathy, although variable, occurs most frequently in the third decade and the disease has a more aggressive course than most other inherited dilated cardiomyopathies (7) . While sudden death from arrhythmias may be prevented by implantation of a pacemaker and/or defibrillator, the progressive heart failure eventually becomes resistant to treatment and heart transplantation is often the last therapeutic option (4) .
We previously discovered abnormally elevated activity of extracellular signal-regulated kinase 1/2 (ERK1/2) in the hearts of Lmna H222P/H222P mice that develop cardiomyopathy (8) . These mice recapitulate the cardiac disease in patients with LMNA mutations and therefore serve as a useful animal model. Inhibition of ERK1/2 signaling in Lmna H222P/H222P mice by an inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2), the enzyme that activates ERK1/2, improved left ventricular ejection fraction and prolonged survival (9) (10) (11) . MEK1/2 inhibitor treatment of these mice further slowed progression of myocardial fibrosis, which is prominent in humans with LMNA cardiomyopathy (10, 11) .
Myocardial fibrosis consists of the replacement of functional cells with accumulation of collagen-rich extracellular matrix (ECM).
Cardiomyocytes are tethered within the ECM, consisting of collagen, elastin, proteoglycans and glycoproteins. ECM provides a scaffold for myofiber alignment protects against sarcomere overstretching and plays a role in electrical behavior of the myocardium. Therefore, ECM stiffness and deposition of fibrous tissue have dramatic effects on heart function (12) . Indeed, myocardial fibrosis contributes to diastolic and systolic dysfunctions and conduction defects in the heart (13, 14) . Pro-fibrotic changes during cardiac remodeling are mainly driven by cytokines such as transforming growth factor-b (TGFb) and the matricellular protein connective tissue growth factor (CTGF/CCN2) (15) . TGF-b-dimers bind to type II receptors, which recruit and phosphorylate type I receptors such as activin receptor-like 5 (ALK5). Ligand binding to this type I receptor recruits and phosphorylates Smad2/3, which is then translocated to the nucleus and activates target gene transcription. We therefore assessed the modulation of TGF-b/Smad signaling implicated in activating fibrosis in Lmna H222P/H222P mice and its interaction with ERK1/2 signaling. We found that TGF-b/Smad signaling participates in the activation of ERK1/2 signaling in LMNA cardiomyopathy and that ERK1/2 acts on CTGF/CCN2 expression to mediate the myocardial fibrosis and left ventricular dysfunction. There was a significant increase of cardiac p-Smad2/3 in Lmna H222P/H222P mouse heart (Fig. 2B) . Immunofluorescence microscopy also revealed a nuclear localization of p-Smad2/3 in the heart from Lmna H222P/H222P mice (Fig. 2C) , which was occurring to a lesser extend in cardiac endothelial cells (Fig. 2D ). This increased nuclear translocation of p-Smad2/3 was confirmed by western blot analysis of fractionated cells (Fig. 2E) . These results demonstrated abnormal activation of TGF-b signaling in hearts from Lmna H222P/H222P mice at an age when myocardial fibrosis occurs. These data extend a previous report showing activation of TGF-b/Smad2/3 signaling in failing hearts from Lmna H222P/H222P mice at 24 weeks of age (16) .
Results

Myocardial fibrosis in
Inhibiting TGF-b/Smad signaling improves cardiac dysfunction
Given the enhanced TGF-b/Smad signaling in hearts of Lmna H222P/H222P mice, we hypothesized that reducing this activity would attenuate myocardial fibrosis and improve cardiac function. We inhibited ALK5, a receptor for TGF-b that recruits and phosphorylates Smad2/3 (17), with daily intra-peritoneal injections of SB-431542 (5 mg/kg) starting at 16 weeks of age (Fig.  3A) . SB-431542 specifically targets the TGF-b signaling (18, 19) . After 4 weeks of treatment, mice were analyzed by echocardiography and sacrificed for biochemical and histological analysis. SB-431542 treatment reduced Smad2/3 phosphorylation in hearts of Lmna H222P/H222P mice compared with DMSO placebo treatment (Fig. 3B) . After the treatment with SB-431542, myocardial fibrosis was reduced in treated Lmna H222P/H222P mice compared with placebo-treated mice (Fig. 3C ). SB-431542 also reduced the levels of Col1a1 and Col1a2 mRNAs in heart (Fig. 3C ). M-mode echocardiography showed that left ventricular end diastolic and end systolic diameters in Lmna H222P/H222P mice treated with SB-431542 were significantly smaller and fractional shortening was significantly increased compared with the placebotreated mice ( Fig. 3D and Table 1 ). SB-431542 also reduced the mRNA levels of NppA and NppB, genes that encode natriuretic peptide precursors that are synthesized in response to left ventricular dilatation, as well as Myl4, the gene encoding the light chain of myosin (Fig. 3E) . Hence, TGF-b/Smad signaling inhibition that reduces fibrosis concomitantly improves left ventricular function in Lmna H222P/H222P mice.
Decreased ERK1/2 activation lowers myocardial fibrosis
We previously showed that reducing ERK1/2 signaling in Lmna H222P/H222P mice, either genetically or using chemical inhibitors, reduces myocardial fibrosis (9) (10) (11) 20 Fig S2B) . Immunohistochemistry also revealed decreased nuclear translocation of p-Smad2/3 when Lmna H222P/H222P mice were treated with PD325901, compared with untreated or DMSO-treated animals (Fig. 4) . In PD325901-treated Lmna These results suggest that ERK1/2 hyperactivation contributes to the enhancement of myocardial fibrosis in the hearts of Lmna H222P/H222P mice.
We next assessed the impact of inhibition of TGF-b signaling on ERK1/2 activity in Lmna H222P/H222P mice. After treatment with SB-431542 for 4 weeks, expression of p-ERK1/2 was lower in protein extracts from hearts of Lmna H222P/H222P mice compared with placebo-treated mice (Fig. 5A ). Smad2/3 phosphorylation paralleled activation of ERK1/2 in hearts of Lmna H222P/H222P mice at 12 and 24 weeks of age (Fig. 5B ). This was confirmed in C2C12 cells stimulated with TGF-b. When cells were treated for 6 h with 2 nM TGF-b1, an increase of both p-Smad2/3 and p-ERK1/2 was observed ( Fig. 5C ). This demonstrated the role played by TGF-b on ERK1/2 signaling in LMNA cardiomyopathy.
Cardiac fibrosis is mediated by CTGF/CCN2 (Fig. 6C ). This increase corresponded to the beginning of fibrosis, as we did not observe any increase of Col1a1 mRNA up to 12 weeks of age and of Col1a2 mRNA up to 16 weeks of age (Fig. 6C ). To test whether the changes we observed in hearts of Lmna H222P/H222P mice also occur in humans, we examined CTGF/CCN2 levels in left ventricular tissue from human subjects with cardiomyopathy caused by mutations in LMNA. Compared with controls, elevated CTGF/CCN2 expression was observed in left ventricles tissue of human subjects with LMNA cardiomyopathy (Fig. 6D ). These observations established that enhanced CTGF/CCN2 expression is a feature of cardiac remodeling in LMNA cardiomyopathy.
CTGF/CCN2 expression influences myocardial fibrosis and left ventricular function
We next hypothesized that reducing CTGF/CCN2 activity would reduce myocardial fibrosis and improve left ventricular function. To test this hypothesis, an inhibitory human monoclonal antibody against CTGF (FG-3019) was administered to Lmna H222P/H222P mice for 2 weeks, starting at 16 weeks of age.
As a control group, Lmna H222P/H222P mice were injected with non-specific human immunoglobulin G (Fig. 7A ). There was less myocardial fibrosis in hearts from Lmna H222P/H222P mice treated with FG-3019 relative to mice treated with control human immunoglobulin G (Fig. 7B ). Consistently, there was a decreased Col1a1 mRNA expression in hearts from Lmna H222P/H222P mice treated with FG-3019 compared with mice treated with control human immunoglobulin G (Fig. 7B ). Two weeks of treatment with FG-3019 significantly improved both the left ventricular end systolic diameter and fractional shortening ( Fig. 7C and Table 2 ). There was also a significant decrease in Myh7 and NppA mRNA expression after the treatment (Fig. 7D ).
ERK1/2 signaling modulates CTGF/CCN2 expression
Given the enhanced ERK1/2 signaling that is observable in hearts of Lmna H222P/H222P mice as early as 4 weeks of age (21), which is before detectable myocardial fibrosis, we hypothesized that ERK1/2 may drive expression of CTGF/CCN2. Treatment of 16 week-old Lmna H222P/H222P mice with a MEK1/2 inhibitor (PD325901) for 1 month significantly decreased Ctgf mRNA in heart compared to that in DMSO-treated mice (Fig. 8A) decreased expression of CTGF/CCN2 (Fig. 8B) . Conversely, the overexpression of ERK2 triggered an increase in CTGF/CCN2 expression (Fig. 8B) .
To test whether expression of the lamin A H222P variant was correlated with CTGF/CCN2 activation, we assessed CTGF/CCN2 promoter activity in stably transfected C2C12 cells overexpressing wild type or H222P lamin A (22) . CTGF/CCN2 promoter activity was increased in transfected cells expressing lamin A H222P compared with cells expressing wild type lamin A (Fig. 8C) . These results demonstrated a correlation between H222P lamin A expression and CTGF/CCN2 expression, recapitulating the expression pattern in hearts from Lmna H222P/H222P mice. We next assessed if the modulation of ERK1/2 signaling caused by H222P lamin A altered CTGF/CCN2 expression. Treatment of transfected C2C12 cells expressing H222P lamin A with PD325901 (10, 5 and 1 mM) showed a dose-dependent decrease in activity of the CTGF/CCN2 promoter (Fig. 8C) . To address whether ERK1/2 activation drove the enhanced CTGF/ CCN2 expression, ERK2 was overexpressed in C2C12 cells expressing lamin A H222P. CTGF/CCN2 expression increased in proportion to the amount of transfected ERK2 while cells transfected with a dominant negative variant of ERK2 did not exhibit elevated CTGF/CCN2 expression (Fig. 8C) . These data demonstrate that cardiac CTGF/CCN2 expression in Lmna Fig. S3B ). These results suggested that in hearts of Lmna H222P/H222P mice TGF-b signaling mediates the activation of ERK1/2, which modulates myocardial fibrosis through up-regulation of CTGF (Fig. 9 ).
Discussion
Cardiac fibrosis exacerbates the clinical progression of heart failure (23, 24) . Therefore, early expression of mediators of fibrosis may contribute to the progressive development of cardiac dysfunction in primary cardiomyopathy. In this study, Lmna H222P/H222P mice were used to explore mechanisms of cardiac fibrosis in dilated cardiomyopathy. At 20 weeks, Lmna The mechanism by which LMNA mutations lead to TGF-b expression and activation remains to be elucidated. However, our study demonstrated some of the pathways by which TGF-b signaling promotes fibrosis. The canonical TGF-b/Smad signaling pathway involves phosphorylation of Smad2 and/or Smad3, which facilitates their interaction with Smad4 and nuclear translocation to induce transcriptional activation of target genes (25, 26) . Lmna H222P/H222P mice exhibited elevated cardiac p-Smad2/3, its enrichment in the nucleus and a concomitant depletion in the cytosol, which are all characteristic of canonical TGF-b/Smad signaling. TGF-b also has several non-canonical functions, one of which involves activation of the ERK1/2 signaling pathway (27) . We have previously reported that ERK1/2 is activated in the hearts of Lmna H222P/H222P mice (8) and that reducing its activity ameliorates development of cardiomyopathy (9) (10) (11) 20) . We have demonstrated that at least one path to ERK1/2 activation in the hearts of Lmna H222P/H222P mice is via TGF-b/Smad signaling, since the ALK5 kinase inhibitor SB-431542 decreased activated ERK1/2. This is in line with a recent finding by Huang et al. (28) , showing that ERK1/2 inhibition resulted in significant decreased of Smad2/3-dependent myocardial fibrosis. The same group also showed that another member of ALK (i.e. ALK7) attenuates cardiac fibrosis by blocking ERK1/2 signaling (28). One of the well-known TGF-b target genes is CTGF. TGF-b can induce CTGF/CCN2 production in cardiac fibroblasts and cardiomyocytes (29) , endothelial cells (30, 31) and pericytes (32) . The regulation of CTGF/CCN2 expression is complex (33) . A TGFb response element located in the promoter region of the CTGF/ CCN2 gene was first reported by Grotendorst et al. (34) and regulation by Smad2/3 binding to the promoter was subsequently confirmed (35) . Our data demonstrate that cardiac CTGF/CCN2 expression is elevated in Lmna H222P/H222P mice, as early as 12 weeks after birth. Inhibition of ERK1/2 activation or genetic depletion of ERK1/2 decreased the expression of CTGF/CCN2 mRNA. This confirmed that CTGF/CCN2 mRNA expression is mediated in part by ERK1/2 signaling (36-38). CTGF/CCN2 was reported to be essential for the sustained fibrotic activity of TGF-b (39) and to promote fibrosis in multiple organs (40) (41) (42) (43) . There are some reports showing that CTGF/CCN2 expression is increased in cardiac fibrosis (44) and failing hearts (23,45,46 ).
However, CTGF/CCN2's mechanism of action is incompletely understood (47) . While it is broadly recognized that TGF-b induces the expression of CTGF/CCN2 (34) , there are also data indicating that CTGF/CCN2 promotes the expression of TGF-b (45, (48) (49) (50) . Thus, CTGF/CCN2 appears to promote TGF-b/Smad signaling by inducing expression of TGF-b in a positive feedback loop. This may involve TGFb-induced ERK1/2 signaling, since inhibition of ERK1/2 strongly reduced CTGF/CCN2 expression and transcription from the CTGF/CCN2 promoter. The effect of CTGF/CCN2 overexpression in cardiac fibroblasts, which are the major cell type responsible for collagen synthesis in the heart, has not yet been examined. Genetic manipulation of CTGF/CCN2 in cardiomyocytes has resulted in a variety of apparently contradictory effects. The first group to generate transgenic mice reported that overexpression of CTGF/ CCN2 in cardiomyocytes did not lead to cardiac fibrosis but the mice developed age-dependent cardiomyopathy that was concordant with cardiac hypertrophy (51). Soon after, Yoon et al. (52) generated transgenic mice overexpressing CTGF/CCN2 in cardiomyocytes. These mice had no cardiac hypertrophy but increased fibrosis upon pressure overload (52) . A contradictory report by others showed that overexpressing CTGF/CCN2 in cardiomyocytes lead to mice with smaller myocytes, enhanced collagen and fibronectin expression and greater blood vessel density but normal left ventricular function (45) . These mice were protected against ischemia/reperfusion injury (45), myocardial infarction (53) and pressure overload (54) . Most recently, transgenic mice were generated that only overexpressed CTGF in cardiomyocytes (55) . After a month of CTGF/CCN2 expression, these mice exhibited no signs of cardiac fibrosis or hypertrophy. It remains unclear if the cause of the discrepant results between these studies is the result of the promoters used to drive CTGF/ CCN2 expression, the background mouse strains or some other reasons.
In the context of the heart, fibrosis can cause increased tissue stiffness, cardiomyocyte atrophy, arrhythmias and hypoxia. Although targeting TGF-b has shown promise as an anti-fibrotic therapy, it also functions in other biological processes (56) . Hence, broad targeting of TGF-b/Smad signaling may be problematic. Inhibiting CTGF/CCN2 may therefore be a more specific target for blocking fibrosis. Similarly, it may be a more specific anti-fibrotic therapy than the anti-protozoal drug, halofuginone, which was reported to attenuate cardiac fibrosis and dysfunction in the mdx mouse model via inhibition of TGF-b/Smad signaling (57, 58) . While some of the data from transgenic mouse models could be interpreted as indicating that inhibition of CTGF/CCN2 might be detrimental to cardiac structure and function, this has not been observed when CTGF/CCN2 was pharmacologically inhibited with antibodies. In a cardiac allograft rejection model, FG-3019 administration for 3 weeks decreased fibrosis in the transplanted heart and suppressed cardiac hypertrophy (59) . In a rat model of bronchopulmonary dysplasia, inhibition of CTGF/CCN2 with FG-3149, a mouse chimera of FG-3019, inhibited hyperoxia-induced increases of right ventricular systolic pressure and prevented right ventricular hypertrophy (60) . And in a transverse aortic constriction-induced mouse model of pressure overload, FG-3149 inhibited cardiac hypertrophy, improved cardiac function and exhibited a trend toward reduced fibrosis that was not significant for the cohort size used (61) . Treating mdx mice with FG-3019 leads also to an improvement in tissue morphology, less fibrosis, a decrease in damage and an improvement in strength of skeletal muscle (62) . These data suggest that CTGF/CCN2 function in the fibrotic process and inhibiting it prevents or reverses fibrosis. In our study, 2 weeks of FG-3019 administration inhibited collagen deposition. Hence, inhibiting CTGF/CCN2 could be beneficial for patients with LMNA cardiomyopathy by reducing cardiac fibrosis.
Established management of LMNA cardiomyopathy included the use of angiotensin-converting enzyme (ACE) inhibitors or the combination of an ACE inhibitor with b-adrenergic receptor blockade (63) . Treatment with ACE inhibitors improves cardiac function in patients and mice with dilated cardiomyopathy; however, ACE inhibition does not attenuate cardiac fibrosis (64, 65) . Modulation of ECM function may prove beneficial in attenuating disease progression, as shown by the success of antifibrotic therapy in the mdx mouse (57, 58) . Future studies will better define the role of CTGF/CCN2 in LMNA cardiomyopathy, as well as determine if CTGF/CCN2 can be a therapeutic target more generally in dilated cardiomyopathy. 
Materials and Methods
Animals
Human heart tissue
Sections of explanted hearts from human subjects with LMNA mutations were obtained from Myobank-AFM de l'lnstitut de Myologie (Paris, France). Myobank-AFM received the authorizations from the French Ministry of Health and from the Comity for Protection of Patient to share tissues and cells of human origin for scientific purposes, ensuring the donors the maintenance of anonymity, respect of their volition, and consent according to the legislation. Control human heart samples were obtained from the National Disease Research Interchange (Philadelphia, PA, USA); information regarding donor confidentiality and consent can be found at http://www.ndriresource.org.
Histology
Hearts from Lmna H222P/H222P mice were fixed in 4% formaldehyde for 48 h, embedded in paraffin, sectioned at 5 mm and stained with Masson trichrome. Representative stained sections were photographed using a Microphot SA (Nikon) light microscope attached to a Spot RT Slide camera (Diagnostic Instruments). Images were processed using Adobe Photoshop CS (Adobe Systems).
Immunohistochemistry and immunofluorescence microscopy
Immunofluorescence staining was performed on frozen 8 lm thick sections of transversal cardiac muscles by fixing them in 3.7% formaldehyde in PBS for 15 min, then blocking in 5% fetal goat serum in PBS/Triton X-100 for 1 h. Sections were incubated in blocking solution with anti-p-smad2/3 antibody (Cell Signaling Technology), CD31 (Abcam) or Col1a1 (Santa Cruz) antibody overnight at 4 C followed by PBS washing and incubation with Texas red-conjugated goat anti-mouse IgG secondary antibody (Invitrogen) and counterstained with 0.1 lg/ml DAPI (Sigma-Aldrich).
Quantitative polymerase chain reaction analysis
Total RNA was extracted using the Rneasy isolation kit (Qiagen). cDNA was synthesized using Superscript first strand synthesis system according to the manufacturer's instructions (Invitrogen) on total RNA. For each replicate in each experiment, RNA from tissue samples of different animals was used. Primers for Col1a1, Col1a2, Fn1, Sdc1, Nid1, Dcn1, Tgf-b1, Tgf-b2 and Ctgf were designed using Primer3 (http://frodo.wi.mit.edu/ cgi-bin/primer3/primer3_www.cgi). Real-time quantitative polymerase chain reaction (qPCR) reactions containing HotStart-IT SYBR green qPCR Master Mix (Affymetrix), 200 nM of each primer and 0.2 ml of template in a 25 ml reaction volume were amplified using the ABI 7300 Real-Time PCR System (Applied Biosystems). Relative levels of mRNA expression calculated using the DDC T method were normalized by comparison to housekeeping mRNA.
Protein extraction and immunoblotting
Mouse heart tissue and cultured cells were homogenized in sample extraction buffer (Cell Signaling) then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and blotted with primary antibodies against Smad2/3 (Santa Cruz Biotechnology), phosphorylated Smad2/3 (Cell Signaling), CTGF (Santa Cruz), ERK1/2 (Santa Cruz Biotechnology), phosphorylated ERK1/2 (Cell Signaling) and GFP, GAPDH (Ambion). Secondary antibodies were horseradish peroxidate-conjugated (GE Healthcare). Recognized proteins were visualized by enhanced chemiluminescence.
Isolation of mouse cardiomyocytes
Wild type and Lmna H222P/H222P mice were anesthetized with pentofurane and ventricular cardiomyocytes were isolated as described previously (8) . Briefly, hearts were removed and the aorta cannulated. After Ca 2þ -free buffer was perfused for 2 min, 0.25 mg/ml collagenase I/II solution was perfused through the coronary arteries for 6 min with 12.5 mM Ca 2þ . Left ventricular tissue was teased apart and pipetted to release individual cells. After enzymatic dispersion, Ca 2þ concentration in the buffer containing bovine serum albumin was elevated in three steps up to 500 mM.
Luciferase assays
C2C12 cells (American Type Culture Collection) were maintained in a humidified 37 C/5% CO 2 incubator and subcultured at 80% confluency. Unmodified and stable C2C12 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen). Stable C2C12 cells were plated at 1 Â 10 6 cells/9.5 cm 2 DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin. Twenty-four hours after plating, the cells were co-transfected with 500 ng of the pGL3-CTGF-Luc, 50 ng of the pGFP-ERK2-DN and 50-100 ng of pGFP-ERK2-WT in OptiMEM medium using Lipofectamine Reagent (Invitrogen). Forty-eight hours after transfection, the luciferase substrate was applied using Luciferase Assay system (Promega). For cell normalization, CellTiterGlo V R Luminescent Cell Viability Assay (Promega) was used.
Thansthoracic echocardiography
Lmna
H222P/H222P mice were anesthetized with 1.5% isoflurane in O 2 and placed on a heating pad (37 C). Echocardiography was performed using a Visualsonics Vevo 770 ultrasound with a 30 MHz transducer applied to the chest wall. Cardiac ventricular dimensions and fractional shortening were measured in 2D mode and M-mode three times for the number of animals indicated. 'Blinded' echocardiographers, unaware of the treatment, performed the examinations.
Statistics
Values for real-time qPCR were compared using an unpaired Student t-test. Comparisons of echocardiographic parameters between PD0325901 and SB-431542-treated and placebo-treated Lmna H222P/H222P mice were performed using a Welch t-test; to validate these results, a non-parametric test (Mann-Whitney) was performed and concordance checked. Statistical analyses were performed using GraphPad Prism software.
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